Selected research
Industry Research
Anti-Viral Drugs Industry Research Report 2026
Market perspective
The global Anti-Viral Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Anti-Viral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Anti-Viral Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Anti-Viral Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Anti-Viral Drugs include Aurobindo Pharma, Bristol-Myers-Squibb, Cipla, Dr Reddy’s, F. Hoffmann-La Roche, AbbVie, GlaxoSmithKline, Merck & Co and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Anti-Viral Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Anti-Viral Drugs Market by Company
Aurobindo Pharma
Bristol-Myers-Squibb
Cipla
Dr Reddy’s
F. Hoffmann-La Roche
AbbVie
GlaxoSmithKline
Merck & Co
Johnson & Johnson
Anti-Viral Drugs Segment by Type
Reverse Transcriptase Inhibitor
Nucleotide Polymerase Inhibitor
Protease Inhibitor
Anti-Viral Drugs Segment by Application
HIV
Influenza
Hepatitis
HSV
Anti-Viral Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Viral Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-Viral Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Viral Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Anti-Viral Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Anti-Viral Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Anti-Viral Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Reverse Transcriptase Inhibitor
- Nucleotide Polymerase Inhibitor
- Protease Inhibitor
Applications
- HIV
- Influenza
- Hepatitis
- HSV
Companies covered
- Aurobindo Pharma
- Bristol-Myers-Squibb
- Cipla
- Dr Reddy’s
- F. Hoffmann-La Roche
- AbbVie
- GlaxoSmithKline
- Merck & Co
- Johnson & Johnson
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Anti-Viral Drugs Market Size (2021-2032)
- 2.2.2 Global Anti-Viral Drugs Sales (2021-2032)
- 2.2.3 Global Anti-Viral Drugs Market Average Price (2021-2032)
- 2.3 Anti-Viral Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Reverse Transcriptase Inhibitor
- 2.3.3 Nucleotide Polymerase Inhibitor
- 2.3.4 Protease Inhibitor
- 2.4 Anti-Viral Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 HIV
- 2.4.3 Influenza
- 2.4.4 Hepatitis
- 2.4.5 HSV
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Anti-Viral Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Anti-Viral Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Anti-Viral Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Anti-Viral Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Anti-Viral Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Anti-Viral Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Anti-Viral Drugs, Product Type & Application
- 3.8 Global Manufacturers of Anti-Viral Drugs, Established Date
- 3.9 Global Anti-Viral Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Aurobindo Pharma
- 4.1.1 Aurobindo Pharma Company Information
- 4.1.2 Aurobindo Pharma Business Overview
- 4.1.3 Aurobindo Pharma Anti-Viral Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Aurobindo Pharma Anti-Viral Drugs Product Portfolio
- 4.1.5 Aurobindo Pharma Recent Developments
- 4.2 Bristol-Myers-Squibb
- 4.2.1 Bristol-Myers-Squibb Company Information
- 4.2.2 Bristol-Myers-Squibb Business Overview
- 4.2.3 Bristol-Myers-Squibb Anti-Viral Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bristol-Myers-Squibb Anti-Viral Drugs Product Portfolio
- 4.2.5 Bristol-Myers-Squibb Recent Developments
- 4.3 Cipla
- 4.3.1 Cipla Company Information
- 4.3.2 Cipla Business Overview
- 4.3.3 Cipla Anti-Viral Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Cipla Anti-Viral Drugs Product Portfolio
- 4.3.5 Cipla Recent Developments
- 4.4 Dr Reddy’s
- 4.4.1 Dr Reddy’s Company Information
- 4.4.2 Dr Reddy’s Business Overview
- 4.4.3 Dr Reddy’s Anti-Viral Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Dr Reddy’s Anti-Viral Drugs Product Portfolio
- 4.4.5 Dr Reddy’s Recent Developments
- 4.5 F. Hoffmann-La Roche
- 4.5.1 F. Hoffmann-La Roche Company Information
- 4.5.2 F. Hoffmann-La Roche Business Overview
- 4.5.3 F. Hoffmann-La Roche Anti-Viral Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 F. Hoffmann-La Roche Anti-Viral Drugs Product Portfolio
- 4.5.5 F. Hoffmann-La Roche Recent Developments
- 4.6 AbbVie
- 4.6.1 AbbVie Company Information
- 4.6.2 AbbVie Business Overview
- 4.6.3 AbbVie Anti-Viral Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 AbbVie Anti-Viral Drugs Product Portfolio
- 4.6.5 AbbVie Recent Developments
- 4.7 GlaxoSmithKline
- 4.7.1 GlaxoSmithKline Company Information
- 4.7.2 GlaxoSmithKline Business Overview
- 4.7.3 GlaxoSmithKline Anti-Viral Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 GlaxoSmithKline Anti-Viral Drugs Product Portfolio
- 4.7.5 GlaxoSmithKline Recent Developments
- 4.8 Merck & Co
- 4.8.1 Merck & Co Company Information
- 4.8.2 Merck & Co Business Overview
- 4.8.3 Merck & Co Anti-Viral Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Merck & Co Anti-Viral Drugs Product Portfolio
- 4.8.5 Merck & Co Recent Developments
- 4.9 Johnson & Johnson
- 4.9.1 Johnson & Johnson Company Information
- 4.9.2 Johnson & Johnson Business Overview
- 4.9.3 Johnson & Johnson Anti-Viral Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Johnson & Johnson Anti-Viral Drugs Product Portfolio
- 4.9.5 Johnson & Johnson Recent Developments
5 Global Anti-Viral Drugs Market Scenario by Region
- 5.1 Global Anti-Viral Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Anti-Viral Drugs Sales by Region: 2021-2032
- 5.2.1 Global Anti-Viral Drugs Sales by Region: 2021-2026
- 5.2.2 Global Anti-Viral Drugs Sales by Region: 2027-2032
- 5.3 Global Anti-Viral Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Anti-Viral Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Anti-Viral Drugs Revenue by Region: 2027-2032
- 5.4 North America Anti-Viral Drugs Market Facts & Figures by Country
- 5.4.1 North America Anti-Viral Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Anti-Viral Drugs Sales by Country (2021-2032)
- 5.4.3 North America Anti-Viral Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Anti-Viral Drugs Market Facts & Figures by Country
- 5.5.1 Europe Anti-Viral Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Anti-Viral Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Anti-Viral Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Anti-Viral Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Anti-Viral Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Anti-Viral Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Anti-Viral Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Anti-Viral Drugs Market Facts & Figures by Country
- 5.7.1 South America Anti-Viral Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Anti-Viral Drugs Sales by Country (2021-2032)
- 5.7.3 South America Anti-Viral Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Anti-Viral Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Anti-Viral Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Anti-Viral Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Anti-Viral Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Anti-Viral Drugs Sales by Type (2021-2032)
- 6.1.1 Global Anti-Viral Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Anti-Viral Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Anti-Viral Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Anti-Viral Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Anti-Viral Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Anti-Viral Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Anti-Viral Drugs Sales by Application (2021-2032)
- 7.1.1 Global Anti-Viral Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Anti-Viral Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Anti-Viral Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Anti-Viral Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Anti-Viral Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Anti-Viral Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Anti-Viral Drugs Value Chain Analysis
- 8.1.1 Anti-Viral Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Anti-Viral Drugs Production Mode & Process
- 8.2 Anti-Viral Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Anti-Viral Drugs Distributors
- 8.2.3 Anti-Viral Drugs Customers
9 Global Anti-Viral Drugs Analyzing Market Dynamics
- 9.1 Anti-Viral Drugs Industry Trends
- 9.2 Anti-Viral Drugs Industry Drivers
- 9.3 Anti-Viral Drugs Industry Opportunities and Challenges
- 9.4 Anti-Viral Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst